Macro Group Pharmaceuticals (Macro Capital) S.A.E reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EGP 526.01 million compared to EGP 729.61 million a year ago. Net loss was EGP 272.65 million compared to net income of EGP 173.84 million a year ago.

Basic loss per share from continuing operations was EGP 0.48 compared to basic earnings per share from continuing operations of EGP 0.3 a year ago. Diluted loss per share from continuing operations was EGP 0.48 compared to diluted earnings per share from continuing operations of EGP 0.3 a year ago.